Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BASE6

Financiado

Cerrado

Targeted Microarrays for 5-hydroxymethylcytosine-based Diagnosis of Hematologica...

Targeted Microarrays for 5-hydroxymethylcytosine-based Diagnosis of Hematological Malignancies 5-hydroxymethylcytosine (5hmC) is an oxidized form of 5-methylcytosine (5mC). It is the first step of reversing DNA methylation and an important indicator of dynamic epigenetic changes in genomic DNA. One characteristic of cancero... ver más

31/05/2024

TAU

Presupuesto desconocido

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-31

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

TAU

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

COMBICODE Decoding the Combinatorial Epigenetic Information of the Mam... Cerrado

CHAMELEON Cellular Hypoxia Alters DNA MEthylation through Loss of Epig... 2M€ Cerrado

PTQ-14-06855 Desarrollo de una herramienta computacional para la identifi... 32K€ Cerrado

CAC-seq. Chemical assisted enrichment of 5 carboxycytosine that also... 213K€ Cerrado

OR-HMC Assay for cancer diagnostics by quantification of 5hmC 150K€ Cerrado

EvoEPIGEN Evolved Replication Systems for Epigenetics 2M€ Cerrado

Duración del proyecto: 17 meses Fecha Inicio: 2022-12-01
Fecha Fin: 2024-05-31

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto 5-hydroxymethylcytosine (5hmC) is an oxidized form of 5-methylcytosine (5mC). It is the first step of reversing DNA methylation and an important indicator of dynamic epigenetic changes in genomic DNA. One characteristic of cancerous transformations is dramatic modulation of the epigenomic landscape. Consequently, changes in the distribution of 5hmC have been shown to correlate with a broad range of cancers and is potentially a powerful disease biomarker. Nevertheless, existing methods for mapping 5hmC are complex and expensive thus hindering the translation of 5hmC research into clinical use. This project aims at developing a custom DNA chip for 5hmC that will allow cost-effective and targeted analysis of disease biomarkers. We will use our patented procedure for direct fluorescent labeling of 5hmC in combination with commercially available genome-wide microarrays to create maps of 5hmC distribution in health and disease. These large-scale arrays will be used in the discovery phase to identify cancer biomarkers. In the second phase, only the subset of genomic loci that contain medically significant modulation in 5hmC will be used to design and print a custom microarray containing only the relevant probes. This concept predicts a cost reduction of 10-100 fold which will remove the barriers for large scale research and high volume testing. Disease specific diagnostic chips are attractive products with direct impact on society and economy via promoting more accessible testing and patient management. Our preliminary results indicate that we will be able to offer a universal platform for even the most challenging samples including cell-free DNA analysis from liquid biopsies. We envision it as an enabling technology for 5hmC research, biomarker discovery and companion diagnostics for guiding and monitoring therapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores